Vivos Therapeutics Posts Strong Revenue Growth Amid Rising OSA Demand
Event summary
- Revenue increased by 35% YoY to $5.2 million in Q2 2026, driven by service revenue from Nevada operations.
- Gross margin improved to 57% in Q2 2026 from 55% in Q2 2025 due to higher revenue and controlled cost of sales.
- Operating expenses rose by 12% YoY to $7.8 million, primarily due to increased salaries and wages post-SCN acquisition.
- Cash position declined to $1.8 million as of June 30, 2026, from $2.0 million at the end of 2025.
The big picture
Vivos Therapeutics is capitalizing on rising demand for non-invasive OSA treatments, leveraging its FDA-cleared CARE devices to drive service revenue growth. The company's strategic initiatives, including AI-enabled software conversion and expanded provider count, aim to address the underserved sleep apnea market. However, sustaining profitability amid increasing operating expenses and cash burn remains a critical challenge.
What we're watching
- Revenue Growth Sustainability
- Whether Vivos can maintain its 35% YoY revenue growth pace amid rising competition in the OSA treatment market.
- Cash Burn Management
- The pace at which Vivos can reduce its cash burn while expanding its provider network and production capacity.
- Strategic Partnerships
- How the finalization of pending partnerships with large multi-center cardiology groups in Florida and Arizona will impact revenue growth.